Debiopharm

Debiopharm Group is a Swiss-based biopharmaceutical company that develops, manufactures, and invests in therapies to address serious diseases. Founded in 1979 by Thierry Mauvernay, the group is headquartered in Switzerland and operates internationally through a portfolio of in-house programs and external collaborations.

The company focuses on moving drug candidates from discovery through development to manufacturing. It maintains end-to-end capabilities, including process development, GMP manufacturing of clinical and commercial supplies, and regulatory support, enabling faster progression of programs from lab bench to patient access. Debiopharm pursues a diversified portfolio primarily in oncology and infectious diseases, combining internal projects with partnerships and licensing arrangements.

Organizationally, Debiopharm operates across several platforms, including drug development, manufacturing, and venture investment. Its investment activities help fund early-stage life sciences companies and strategic collaborations with biotech and pharmaceutical partners. The group also runs initiatives such as the Debiopharm Innovation Forum to connect innovators with potential collaborators and investors.

Global footprint: while centered in Switzerland, Debiopharm collaborates with partners worldwide and maintains manufacturing capacity to support clinical trials and, in some cases, commercial supply. The company emphasizes an integrated model of development, manufacturing, and investment to accelerate access to therapies.